Grifols Sa's Comment on Sales, Marketing and Customers
The company serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. Its Nucleic Acid Testing (NAT) Donor Screening Unit develops assays and instruments for transfusion and transplantation screening. In 2025, the Diagnostic business unit generated €640 million, representing 8.5% of total net revenue. The Bio Supplies unit, which focuses on biological products for non-therapeutic use and plasma sales, accounted for €154 million or 2.0% of revenue. Other activities, including manufacturing services, third-party plasma sales, research, and Healthcare Solutions, contributed €243 million or 3.2%.
The company operates in over 100 countries with subsidiaries in more than 30 countries. The United States and Canada account for 56.5% of total net revenue, the European Union 21.5% (with 25.9% of EU revenue from Spain), and the rest of the world 22.0%. Key growth markets include emerging economies in Latin America—such as Mexico, Colombia, Argentina, Chile, and Brazil—and the Asia-Pacific region, including Malaysia, China, Thailand, Singapore, Australia, Japan, India, Hong Kong, Taiwan, and Indonesia. The company also maintains a presence in the Middle East, specifically in Dubai and Saudi Arabia.
The company is one of the three largest global producers of plasma derivatives, alongside Takeda and CSL Group, and is the largest producer of alpha-1 proteinase inhibitor (A1PI) for treating A1PI deficiency-related emphysema.
Expansion of XEMBIFY® Label in the U.S. Augments Treatment Options for Primary Humoral Immunodeficiencies Grifols, a global leader in the production of plasma-derived medicines, has recently received approval from the United States Food and Drug Administration (FDA) for an expanded label for XEMBIFY® (immune globulin subcutaneous human-klhw). This approval marks a significant milestone for the company, allowing its 20% subcutaneous immunoglobulin (SCIg) to be administered to treatment-naive patients with primary humoral immunodeficiencies (PI). Primary humoral immunodeficiencies are a group of disorders characterized by the immune system s inability to produce sufficient antibodies, making affected individ...
Grifols Sa’s Comment on Sales, Marketing and Customers
The company serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. Its Nucleic Acid Testing (NAT) Donor Screening Unit develops assays and instruments for transfusion and transplantation screening. In 2025, the Diagnostic business unit generated €640 million, representing 8.5% of total net revenue. The Bio Supplies unit, which focuses on biological products for non-therapeutic use and plasma sales, accounted for €154 million or 2.0% of revenue. Other activities, including manufacturing services, third-party plasma sales, research, and Healthcare Solutions, contributed €243 million or 3.2%.
The company operates in over 100 countries with subsidiaries in more than 30 countries. The United States and Canada account for 56.5% of total net revenue, the European Union 21.5% (with 25.9% of EU revenue from Spain), and the rest of the world 22.0%. Key growth markets include emerging economies in Latin America—such as Mexico, Colombia, Argentina, Chile, and Brazil—and the Asia-Pacific region, including Malaysia, China, Thailand, Singapore, Australia, Japan, India, Hong Kong, Taiwan, and Indonesia. The company also maintains a presence in the Middle East, specifically in Dubai and Saudi Arabia.
The company is one of the three largest global producers of plasma derivatives, alongside Takeda and CSL Group, and is the largest producer of alpha-1 proteinase inhibitor (A1PI) for treating A1PI deficiency-related emphysema.
Sources:
Grifols Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Grifols Sa’s corporate clients.
For your research, we’ve provided 9 tables on Grifols Sa corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
86.22 %